Identifying Therapeutic Targets for Bronchial Asthma: Systematic Druggable Genome-Wide Mendelian Randomization

Area of Science:

• Genetics and Genomics
• Pharmacology
• Respiratory Medicine

Background:

• Asthma treatment remains a significant challenge.
• Mendelian randomization (MR) is a powerful tool for identifying therapeutic targets.
• A systematic MR analysis was conducted across the druggable genome to find novel asthma targets.

Purpose of the Study:

• To explore and identify new potential therapeutic targets for asthma treatment.
• To systematically analyze druggable genes for their association with asthma.
• To guide the development of more effective asthma therapies.

Main Methods:

• Screened druggable genes using lung and blood expression quantitative trait loci (eQTL) data.
• Performed MR and colocalization analyses to identify asthma-associated genes.
• Conducted phenome-wide, enrichment, and protein-protein interaction (PPI) network analyses.

Main Results:

• Identified six druggable genes significantly associated with asthma.
• Five genes (IRF1, OXER1, PSMA4, UNC13D, HLA-DRB1) were found in whole blood, and one (CD226) in lung tissue.
• Enrichment analysis confirmed associations with asthma pathways, and phenome-wide analysis indicated minimal side effects.

Conclusions:

• Identified six promising drug targets for asthma treatment.
• These discoveries offer potential for more effective asthma therapies.
• The findings may help reduce drug development costs for asthma.